Compare ResMed Inc. (RMD) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs United Airlines Holdings Inc — how do they compare? ResMed Inc. trades at $225.05 (market cap $32.61B), while United Airlines Holdings Inc trades at $125.24 (market cap $41.00B). The key difference: United Airlines Holdings Inc is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| RMD | UAL | |
|---|---|---|
Market Cap | $32.61B | $41.00B |
Sector | Health | Industrials |
52-Week High | $293.73 | $136.11 |
52-Week Low | $182.82 | $85.21 |
Enterprise Value | $31.97B | $58.03B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
United Airlines (UAL) trades at $125.32, up 1.26% today, with strong technical momentum and consistent earnings beats. The stock shows bullish moving averages and trades near resistance at $126. Fundamentals are solid, with revenue growth to $59.07B in 2025 and net income of $3.35B, supported by a low P/E of 11.83. Recent news highlights fuel cost management and merger speculation, though operational disruptions pose near-term risks.
Outlook remains positive with a consensus price target of $167.73, implying 34% upside. Opportunities include robust travel demand and cost controls, but risks involve volatile fuel prices, competitive pressure, and execution challenges. Analyst sentiment is strongly bullish with 66% buy ratings, though investors should monitor margin sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
